AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
22:00
Luca Niculescu supports Marian Neacșu for the Ministry of Internal Affairs
21:54
The Competition Council authorizes the Maisadour-Euralis merger, active in Romania in the seed market and poultry sector
21:39
Cristela Georgescu accuses authorities of political persecution and criticizes the annulment of the 2024 presidential election in an interview given to influencer Mario Nawfal on X
21:25
Donald Trump's spokesperson, Katie Zacharia, fired after less than a week
21:22
Acting Prime Minister, warning to the Niculescu Government: “The most dangerous adversary is still the PSD”
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
